Clinical trial
Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2)
NCT05655013 is registered in ClinicalTrials.gov with Aarhus University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2)
- Lead sponsor
- Aarhus University Hospital
- Phase
- Phase 4
- Overall status
- Active, not recruiting
- Start date
- May 10, 2023
- Completion date
- February 1, 2027
- Enrollment
- 200 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.